CEPHEID

Manufacture and commercialize clinical molecular diagnostic tests

2200 Pennsylvania Ave NW Suite 800W Washington DC 20037, Washington, DC  ·  ANGELA STEWART

Filings
65
Clients
1
Total Income
Years Active
2008–2024

Filings

Year Client Period Income Expenses Doc
2024 CEPHEID 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Termination
$10,000
2024 CEPHEID 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
$200,000
2024 CEPHEID 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report
$200,000
2023 CEPHEID 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report
$200,000
2023 CEPHEID 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
$200,000
2023 CEPHEID 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
$200,000
2023 CEPHEID 1st Quarter (Jan 1 - Mar 31)
1st Quarter - Report
$190,000
2022 CEPHEID 4th Quarter (Oct 1 - Dec 31)
4th Quarter - Report
$140,000
2022 CEPHEID 3rd Quarter (July 1 - Sep 30)
3rd Quarter - Report
$140,000
2022 CEPHEID 2nd Quarter (Apr 1 - June 30)
2nd Quarter - Report
$140,000
Page 1 of 7  ·  65 filings Next

Clients Represented

ClientFilingsTotal Income
CEPHEID 65

Lobbyists

NameDisclosed Prior Position
HALLIE CHRISTINE LEWIS Manager, Government Relations
THARINI SATHIAMOORTHY
MICHELE M SCHOONMAKER Executive Director, Government Affairs
ANGELA STEWART Legislative Counsel, Senator John W. Warner (R-VA)

Affiliated Organizations

DANAHER
Washington, DC, US